ICU Medical (NASDAQ:ICUI) Research Coverage Started at Jefferies Financial Group

Jefferies Financial Group initiated coverage on shares of ICU Medical (NASDAQ:ICUI) in a research note issued to investors on Monday morning, Marketbeat Ratings reports. The firm issued a hold rating and a $183.00 target price on the medical instruments supplier’s stock.

Several other research firms have also issued reports on ICUI. StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Thursday, September 12th. Raymond James raised their price objective on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research note on Thursday, September 12th. KeyCorp upped their target price on ICU Medical from $136.00 to $147.00 and gave the company an “overweight” rating in a research note on Thursday, August 8th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a report on Thursday, October 10th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, ICU Medical has an average rating of “Moderate Buy” and an average target price of $170.25.

ICU Medical Trading Up 2.4 %

Shares of NASDAQ ICUI opened at $183.83 on Monday. The stock has a market capitalization of $4.48 billion, a P/E ratio of -75.03 and a beta of 0.66. ICU Medical has a 1-year low of $78.28 and a 1-year high of $188.53. The business’s 50 day moving average is $168.94 and its two-hundred day moving average is $131.20. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.41 and a quick ratio of 1.08.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.56. The firm had revenue of $596.50 million for the quarter, compared to the consensus estimate of $556.64 million. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. The company’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.58 EPS. As a group, research analysts expect that ICU Medical will post 3.76 EPS for the current year.

Insider Activity at ICU Medical

In other ICU Medical news, VP Daniel Woolson sold 2,502 shares of ICU Medical stock in a transaction on Friday, August 30th. The stock was sold at an average price of $163.22, for a total transaction of $408,376.44. Following the completion of the sale, the vice president now directly owns 13,107 shares of the company’s stock, valued at $2,139,324.54. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the transaction, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at $16,320,691.72. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Daniel Woolson sold 2,502 shares of the stock in a transaction on Friday, August 30th. The shares were sold at an average price of $163.22, for a total value of $408,376.44. Following the sale, the vice president now directly owns 13,107 shares in the company, valued at $2,139,324.54. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 40,552 shares of company stock worth $6,679,322. Company insiders own 6.70% of the company’s stock.

Institutional Investors Weigh In On ICU Medical

A number of institutional investors have recently added to or reduced their stakes in the stock. Scout Investments Inc. lifted its position in ICU Medical by 16.3% during the first quarter. Scout Investments Inc. now owns 51,819 shares of the medical instruments supplier’s stock valued at $5,463,000 after acquiring an additional 7,272 shares during the last quarter. Wakefield Asset Management LLLP acquired a new position in shares of ICU Medical during the first quarter worth $989,000. Vanguard Group Inc. lifted its holdings in shares of ICU Medical by 14.8% during the 4th quarter. Vanguard Group Inc. now owns 2,440,729 shares of the medical instruments supplier’s stock valued at $243,438,000 after purchasing an additional 315,103 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of ICU Medical by 441.7% in the 2nd quarter. SG Americas Securities LLC now owns 5,818 shares of the medical instruments supplier’s stock worth $691,000 after purchasing an additional 4,744 shares in the last quarter. Finally, Sei Investments Co. grew its stake in ICU Medical by 52.1% during the 1st quarter. Sei Investments Co. now owns 28,586 shares of the medical instruments supplier’s stock worth $3,068,000 after buying an additional 9,793 shares during the last quarter. Institutional investors own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.